VCANBIO(600645)2022-10-28 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥407,415,406.55, representing a year-on-year increase of 4.01%[6] - The net profit attributable to shareholders for Q3 2022 was ¥49,718,296.95, a decrease of 37.94% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 111.58% year-on-year, indicating strong growth in reagent business revenue[13] - The basic earnings per share for Q3 2022 was ¥0.10, down 41.18% from the previous year[9] - Net profit for the third quarter of 2022 was ¥113,460,668.07, down from ¥194,586,517.04 in the same quarter of 2021, reflecting a decrease of approximately 41.7%[33] - The company reported a total comprehensive income of ¥81,470,494.05 for the third quarter of 2022, compared to ¥186,621,508.15 in the same quarter of 2021, a decrease of about 56.4%[35] - The company experienced a decrease in investment income, reporting ¥2,188,625.17 in 2022 compared to ¥20,486,959.81 in 2021, a decline of about 89.3%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,226,937,505.02, an increase of 3.85% compared to the end of the previous year[9] - As of September 30, 2022, the company's total assets amounted to RMB 5,226,937,505.02, an increase from RMB 5,033,377,672.10 as of December 31, 2021, representing a growth of approximately 3.84%[22] - The total liabilities of the company were RMB 1,596,406,723.50, compared to RMB 1,500,617,384.63 at the end of 2021, reflecting a rise of approximately 6.38%[28] - The total owner's equity was RMB 3,630,530,781.52, reflecting a stable position compared to the previous year[28] - The company’s total liabilities and equity increased to ¥5,226,937,505.02 in 2022 from ¥5,033,377,672.10 in 2021, reflecting a growth of approximately 3.8%[30] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥178,308,231.45, reflecting a decrease of 23.34%[9] - The net cash flow from operating activities was 178,308,231.45, a decrease of 23.3% compared to 232,588,634.00 from the previous period[40] - Total cash inflow from financing activities was 17,500,000.00, significantly higher than 692,100.00 in the previous period[42] - The net cash flow from investing activities was -71,251,901.56, an improvement from -92,456,340.77 in the previous period[40] - Cash and cash equivalents at the end of the period reached 1,317,810,007.20, up from 1,176,968,867.46 in the previous period[42] - The total cash outflow from financing activities was 39,740,742.26, compared to 22,629,667.81 in the previous period, indicating increased financial obligations[42] - The cash inflow from operating activities totaled 1,235,684,087.35, slightly down from 1,245,397,088.82 in the previous period[40] - The cash outflow for purchasing goods and services was 299,916,803.09, an increase from 283,025,699.27 in the previous period[40] - The company received tax refunds amounting to 4,749,499.19, compared to 1,193,803.99 in the previous period, showing improved tax recovery[40] - The cash inflow from investment activities was 3,025,864.67, a significant decrease from 71,836,563.12 in the previous period[40] - The net increase in cash and cash equivalents for the period was 127,737,045.60, compared to 116,649,488.84 in the previous period[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,183[14] - The largest shareholder, Tianjin Deyuan Health Management Co., Ltd., held 12.14% of the shares, with a significant portion pledged[16] Research and Development - Research and development expenses for the first three quarters of 2022 were ¥109,497,085.50, up from ¥102,165,541.66 in 2021, marking an increase of about 7.3%[30]